network pharmacology-based approach to investigate the analgesic efficacy and molecular targets of xuangui dropping pill for treating primary dysmenorrhea
Clicks: 201
ID: 192015
2017
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
201 views
35 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #423 of 899 articles by views in ACS applied materials & interfaces
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 899 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
This study aimed to evaluate the clinical analgesic efficacy and identify the molecular targets of XGDP for treating primary dysmenorrhea (PD) by a network pharmacology approach. Analysis of pain disappearance rate of XGDP in PD treatment was conducted based on data from phase II and III randomized, double-blind, double-simulation, and positive parallel controlled clinical trials. The bioactive compounds were obtained by the absorption, distribution, metabolism, and excretion processes with oral bioavailability (OB) and drug-likeness (DL) evaluation. Subsequently, target prediction, pathway identification, and network construction were employed to clarify the mechanisms of the analgesic effect of XGDP on PD. The pain disappearance rates in phase II and III clinical trials of XGDP in PD treatment were 62.5% and 55.8%, respectively, yielding a significant difference (P<0.05) when compared with the control group using Tongjingbao granules (TJBG). Among 331 compounds, 53 compounds in XGDP were identified as the active compounds related to PD through OB, DL, and target prediction. The active compounds and molecular targets of XGDP were identified, and our study showed that XGDP may exert its therapeutic effects on PD through the regulation of the targets related to anti-inflammation analgesia and central analgesia and relieving smooth muscle contraction.
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (122 words).
Try re-searching for a better abstract.
| Reference Key |
huang2017evidence-basednetwork
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Jihan Huang;Lei Li;Fan Cheung;Ning Wang;Yunfei Li;Zhenyu Fan;Fang Yin;Juan Yang;Rui Gao;Yingchun He;Yibin Feng |
| Journal | ACS applied materials & interfaces |
| Year | 2017 |
| DOI |
10.1155/2017/7525179
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.